ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1590

Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases

Niti Pawar1, Kimberly E. Taylor1, Monica Yang1, Parakkal Deepak2, Wooseob Kim2, Michael Paley3, Mehrdad Matloubian1, Alex Carividi1, Matthew Ciorba2, Emanuel Demissie1, Alia A. El-Qunni,2, Katherine Huang2, Baylee Kinnett2, Lily E. McMorrow2, Diana Paez1, Abbey Rose2, Rebecca E. Schriefer2, Ali H Ellebedy2, Alfred Kim2, Mary Nakamura4, Patricia Katz1 and Lianne Gensler5, 1University of California San Francisco, San Francisco, CA, 2Washington University School of Medicine, St. Louis, MO, 3Washington University in St. Louis, Olivette, MO, 4UCSF/SFVAHCS, San Francisco, CA, 5Department of Rheumatology, University of California San Francisco, San Francisco, CA

Meeting: ACR Convergence 2021

Keywords: Anxiety, COVID-19, mental health, Patient reported outcomes, sleep

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Patient Outcomes, Preferences, & Attitudes Poster IV: COVID-19 (1589–1613)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: As the COVID-19 pandemic unfolded, people across the world experienced a psychological burden with social confinement, concerns about health, potential infection, jobs, financial difficulty, and uncertainty about the future. Immunosuppressed patients with chronic inflammatory diseases (CID) may have experienced an additional burden with their immunocompromised status. The purpose of this study was to examine patient-reported outcomes over time in patients with CID undergoing SARS-CoV2 vaccination.

Methods: This is a prospective cohort of patients at two sites with CID undergoing SARS-CoV2 vaccination. Participants completed 3 study visits (baseline before vaccination (T1), after dose 1 (T2), and after dose 2 (T3)) where blood and clinical data were collected. Patient-reported outcomes were measured with the PROMIS-29, which includes 4-item scales for 7 domains (physical function, fatigue, anxiety, depression, sleep disturbance, social participation, pain interference) and a 1-item pain severity question. PROMIS-29 scales were summed and converted to T scores (population mean [SD] of 50 [10]). Mixed effects models were used to examine how the PROMIS scores compared to baseline after both vaccination doses, adjusting for age, gender and study site.

Results: The cohort was 72% female with a mean (± SD) age of 48.1±15.5 years (Table 1). In the overall cohort, sleep disturbance significantly improved after both doses of SARS-CoV2 vaccinations (T score -2.5, 95%CI -3.4, -1.6) (Tables 2). Anxiety improved after the second vaccine dose. Improvements in each were within the range of estimated minimally important differences (MID). Physical function worsened, although this did not meet the MID threshold (-1.0, 95% CI -1.6, -0.4). In an analysis stratified by levels of baseline anxiety (High anxiety: PROMIS Anxiety ≥55 vs < 55), improvement in anxiety at T3 was greater for the higher versus lower anxiety group (-5.4, 95% CI -7.2, -3.6 [T3 T1] vs. -3.7, 95%CI -5.6, -1.8). Improvements in fatigue (-2.1, 95% CI -3.6, -0.5) and social participation (2.3, 95% CI 0.5, 4.2) were also noted for the high-anxiety group (Table 2). Similar to the overall cohort, physical function worsened slightly for both groups and sleep disturbance improved significantly.

Conclusion: With the completion of the SARS-CoV2 vaccine series, sleep disturbance decreased in a significant and meaningful way in patients with CID. In patients with higher anxiety at baseline, not only did anxiety decrease, but so did fatigue and sleep disturbance in addition to an increase in social participation. Overall, this suggests vaccines may lead to improvements in mental health and wellbeing of patients with CID, particularly among those with greater anxiety.

Adjusted for age, gender and study site


Disclosures: N. Pawar, None; K. E. Taylor, None; M. Yang, None; P. Deepak, Abbvie, 1, Takeda Pharmaceuticals LLC, 5, Janssen Pharrmaceuticals, 1, Pfizer, 1, Prometheus Biosciences, 1, Boehringer Ingelheim, 1, 5, Arena Pharmaceuticals, 1, 5, Bristol-Myers Squibb-Celgene, 5; W. Kim, None; M. Paley, None; M. Matloubian, Virtuoso Therapeutics Inc., 2; A. Carividi, None; M. Ciorba, Abbvie, 2, Pfizer, 2, 5, BMS, 2, Theravance, 2, Incyte, 5, Janssen, 5; E. Demissie, None; A. El-Qunni,, None; K. Huang, None; B. Kinnett, None; L. McMorrow, None; D. Paez, None; A. Rose, None; R. Schriefer, None; A. Ellebedy, Emergent BioSolutions, 5, Abbvie, 5; A. Kim, Kypha, Inc., 5, GlaxoSmithKline, 2, 5, 6, Alexion Pharmaceuticals, 2, Annexon Biosciences, 2, Aurinia Pharmaceuticals, 2, 6; M. Nakamura, None; P. Katz, None; L. Gensler, Novartis, 5, UCB, 5, Eli Lilly, 2, Gilead, 2, Pfizer, 2, Pfizer, 5, Janssen, 2, UCB, 2.

To cite this abstract in AMA style:

Pawar N, E. Taylor K, Yang M, Deepak P, Kim W, Paley M, Matloubian M, Carividi A, Ciorba M, Demissie E, El-Qunni, A, Huang K, Kinnett B, McMorrow L, Paez D, Rose A, Schriefer R, Ellebedy A, Kim A, Nakamura M, Katz P, Gensler L. Sleep Disturbance Improves with SARS-COV2 Vaccinations in Patients with Rheumatologic and Chronic Inflammatory Diseases [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/sleep-disturbance-improves-with-sars-cov2-vaccinations-in-patients-with-rheumatologic-and-chronic-inflammatory-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sleep-disturbance-improves-with-sars-cov2-vaccinations-in-patients-with-rheumatologic-and-chronic-inflammatory-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology